Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Organisation › Details

BioNTech RNA Pharmaceuticals GmbH

BioNTech RNA Pharmaceuticals GmbH is a fully-owned subsidiary company within the BioNTech AG Group. The company is a technology leader in the rapidly growing field of synthetic messenger RNA (mRNA) therapeutics. Its system is based on the precise delivery of potent, long-lived synthetic mRNA into target cells. Following delivery of the mRNA, patients’ cells produce the mRNA-encoded protein, which is the pharmacologically active product. BioNTech is currently performing clinical trials to develop the concept of tailored multivalent Mutanome Vaccines. *


Period Start 2014-03-06 renamed
  Group BioNTech (Group)
  Predecessor Ribological GmbH
Products Industry BIOTECH
  Industry 2 RNAi drug (RNAi therapeutic)
Persons Person Pötting, Sierk (BioNTech 201409– CFO before Sandoz Inc/Novartis + McKinsey)
  Person 2 Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
Region Region Mainz
  Country Germany
  Street 12 An der Goldgrube
  City 55131 Mainz
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2011-12-25)
    * Document for �About Section�: 
Record changed: 2017-04-01


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top